CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 34 enrolled
Drug / intervention
RBX2660 (microbiota suspension)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01925417
NCT01925417Phase 2Completed
CompareCT.gov

A Phase 2 Open-label Clinical Trial Demonstrating the Safety of RBX2660 Microbiota Suspension for the Treatment of Recurrent Clostridium Difficile-associated Diarrhea (CDAD): the PUNCH CD Study

Rebiotix Inc.·interventional·Posted Aug 19, 2013·Updated Nov 13, 2019

In Brief

A Phase 2 clinical trial evaluating RBX2660 (microbiota suspension) for Recurrent Clostridium Difficile Infection. Completed, enrolled 34 participants across 13 sites.

Detailed Summary

This study will assess the safety of a new biologic drug, RBX2660 (microbiota suspension) as a treatment for recurrent Clostridium difficile-associated diarrhea (CDAD), which is the primary symptom of recurrent Clostridium difficile infection. All eligible subjects will receive RBX2660.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Clostridium Difficile Infection
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 19, 2013
Enrollment StartAug 1, 2013
Primary CompletionMar 1, 2014
Study CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 12.9 years ago

Interventions

RBX2660 (microbiota suspension)biological